# OnCo record cemiplimab-advanced-bcc (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/cemiplimab-advanced-bcc/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "cemiplimab-advanced-bcc", "NCT03132636" ;
  schema:name "Cemiplimab in basal cell carcinoma after a hedgehog inhibitor"@en ;
  schema:alternateName "Study 1620"@en, "cemiplimab in locally advanced basal cell carcinoma"@en ;
  schema:description "Before this trial there was nothing to offer someone whose basal cell carcinoma had outgrown or outlasted the hedgehog pill. Immunotherapy shrank the tumour in about a third of them, and it is now the standard second treatment."@en ;
  schema:url <https://onco.cc/trials/cemiplimab-advanced-bcc/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03132636>, <https://doi.org/10.1016/S1470-2045(21)00126-1>, <https://pubmed.ncbi.nlm.nih.gov/34000246/> ;
  onco:status "positive" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/basal-cell-carcinoma/>, <https://onco.cc/cancers/locally-advanced-bcc/>, <https://onco.cc/cancers/skin-cancer/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/cemiplimab/> ;
  onco:companies <https://onco.cc/companies/regeneron/>, <https://onco.cc/companies/sanofi/> ;
  onco:terms <https://onco.cc/terms/hedgehog-inhibitor-tolerability/>, <https://onco.cc/terms/irae/>, <https://onco.cc/terms/tmb/> ;
  onco:trials <https://onco.cc/trials/erivance/>, <https://onco.cc/trials/bolt/>, <https://onco.cc/trials/stevie/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-cemiplimab-bcc-stratigos-lancet-oncol-2021/> .